/

IOVA

Iovance Biotherapeutics, Inc.Open

14.38−0.18 −1.24%USD

NasdaqGM · as of Oct 13, 11:21 ET · 15m delay

Open

14.48

Prev close

14.56

Day range

14.3214.68

52-week range

1.7615.30

Volume

2.68M0.15×

Mkt cap

6.51B

P/E ttm

—

Fwd P/E

-73.46

EPS ttm

-0.6900

Div yield

0.00%

Earnings

Aug 6, 2026

From 52w high

−6.01%

Price Chart

Yahoo Finance · delayed

IOVAOct 13, 2026O 14.48H 14.68L 14.31C 14.38−0.18 (−1.24%)Vol 2.68M

SMA 509.57
SMA 2005.13

1Y change +584.76% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

IOVA Iovance Biotherapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +10.96%
1 month: +67.21%
3 months: +265.90%
6 months: +295.05%
Year to date: +426.74%
1 year: +571.96%

Valuation & ownership

Market cap: 6.51B
Enterprise value: 6.34B
P/E (ttm): —
Forward P/E: -73.46
PEG ratio: —
Price / book: 8.85
Price / sales (ttm): 20.04
EV / EBITDA: -24.44
EPS (ttm): -0.6900
EPS (forward): -0.1958
Beta (5y monthly): 0.76
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 452.97M
Float: 394.31M
Short % of float: 15.31%
Short ratio (days): 3.69
Held by insiders: 0.35%
Held by institutions: 70.72%
Avg volume (3m): 17.86M
50-day average: 9.36
200-day average: 5.07
52-week change: +571.96%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): overbought 70.5
vs 50-day SMA: +50.34%
vs 200-day SMA: +180.55%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 5.96%
Realised vol (20d, ann.): 113.2%
From 52-week high: −6.01%
From 52-week low: +717.05%

ANR

Analyst Consensus

10 analysts

Consensus

Buy

1.60 on a 1 (strong buy) – 5 (sell) scale

Mean target

14.40

+0.14% implied

Low 7.00Median 15.50High 20.00

Recommendation trend

Now8 / 2 / 0
1m ago8 / 2 / 0

DES

About Iovance Biotherapeutics, Inc.

Yahoo Finance profile

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 975
Headquarters: San Carlos, CA, United States
Website: iovance.com
Officers

SEAS

Seasonality · IOVA

2010–2026 · monthly returns

Strongest month Jul +22.89%Weakest month Apr −6.57%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-6.6	51.4	-9.1	-4.3	22.0	1.5	-2.2	100.7	81.4	-3.0			+426.7%
2025	-20.9	-27.5	-21.5	7.8	-51.3	-1.7	49.4	-13.2	-2.7	-9.2	25.4	10.5	−63.1%
2024	-4.9	105.8	-6.9	-20.5	-24.6	-9.7	8.9	33.6	-19.5	11.2	-10.7	-20.6	−9.0%
2023	24.6	-8.4	-16.2	-7.7	55.0	-19.5	3.1	-16.8	-24.7	-16.0	58.9	33.9	+27.2%
2022	-12.8	-5.9	6.3	-9.0	-55.4	63.6	5.5	-8.0	-10.6	-2.5	-31.5	-0.2	−66.5%
2021	-5.5	-14.9	-15.1	-0.7	-40.9	40.1	-14.4	8.1	2.5	-1.4	-23.0	2.0	−58.9%
2020	-21.5	51.4	-9.0	7.4	-0.2	-14.5	5.9	14.7	-1.2	8.4	8.8	19.6	+67.6%
2019	3.4	12.2	-7.4	19.9	43.4	50.0	0.3	-14.6	-13.4	16.1	8.0	21.2	+212.8%
2018	94.4	11.6	-2.6	-14.2	0.7	-12.3	10.9	24.6	-36.4	-19.3	6.5	-8.5	+10.6%
2017	4.3	5.5	-2.6	-8.1	-24.8	42.7	-20.4	-1.7	34.8	0.4	16.3	-11.6	+15.1%
2016	-22.4	-6.8	-9.0	11.6	4.1	37.3	9.1	-10.0	3.4	-24.1	6.4	4.5	−10.0%
2015	-0.3	14.4	34.9	-1.5	-6.2	-18.1	-6.7	-16.9	-19.0	12.3	12.5	6.0	−1.9%
2014	-53.0	12.0	71.0	-8.9	-12.8	-14.7	11.7	-3.8	3.9	-10.6	-3.8	28.0	−25.0%
2013	-50.0	-27.3	-25.0	-66.7	150.0	-60.0	250.0	-14.3	9.2	-27.5	77.3	24.7	−52.3%
2012	5.0	9.5	0.0	-13.9	-24.2	-40.0	33.3	-20.0	-16.7	-15.0	11.8	-42.1	−78.0%
2011	0.0	0.8	-4.8	5.8	4.7	9.0	-3.4	-27.9	-1.0	25.0	-2.4	-18.0	−20.0%
2010											-6.4	21.4	+13.6%

INSD

Insider Activity · IOVA

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Sep 7, 2026	Vogt Frederick GChief Executive Officer	—	15.6K	—
Sep 7, 2026	Puri Raj KOfficer	—	9.8K	—
Sep 7, 2026	Bilinsky Igor PChief Operating Officer	—	7.8K	—
Aug 31, 2026	Vogt Frederick GChief Executive Officer	—	41.7K	—
Aug 31, 2026	Puri Raj KOfficer	—	5.5K	—
Aug 31, 2026	Bilinsky Igor PChief Operating Officer	—	8.8K	—
Aug 9, 2026	Kirby Daniel GordonOfficer	—	10K	—
Aug 5, 2026	Roche Corleen MChief Financial Officer	—	50K	—
Jun 4, 2026	Vogt Frederick GChief Executive Officer	—	15.6K	—
Jun 4, 2026	Graf Finckenstein FriedrichOfficer	—	7.8K	—
Jun 4, 2026	Puri Raj KOfficer	—	9.8K	—
Jun 4, 2026	Bilinsky Igor PChief Operating Officer	—	7.8K	—
May 31, 2026	Vogt Frederick GChief Executive Officer	—	41.7K	—
May 31, 2026	Graf Finckenstein FriedrichOfficer	—	8.8K	—
May 31, 2026	Puri Raj KOfficer	—	5.5K	—
May 31, 2026	Bilinsky Igor PChief Operating Officer	—	8.8K	—
May 10, 2026	Kirby Daniel GordonOfficer	—	10K	—
Mar 4, 2026	Vogt Frederick GChief Executive Officer	—	62.5K	—
Mar 4, 2026	Graf Finckenstein FriedrichOfficer	—	31.2K	—
Mar 4, 2026	Puri Raj KOfficer	—	39.1K	—

IOVA

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

IOVA

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Iovance Biotherapeutics, Inc.

Seasonality · IOVA

Insider Activity · IOVA

Congress Trades · IOVA

Investors Holding IOVA

Investors Holding IOVA

Congress Trades · IOVA

Seasonality · IOVA

Insider Activity · IOVA

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Iovance Biotherapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News